Why Beauty Brands Should Own Their Formulas Before Fundraising
“The worst time to figure out who owns your hero formula is when an investor is already doing due diligence on the company.”
A beauty founder can spend years building a product, growing sales, earning reviews, and attracting investor interest before discovering something surprisingly fundamental:
The company may not actually own the formula behind its hero product.
Paying for product development does not automatically establish formula ownership. The answer depends on the agreements between the brand, formulator, laboratory, manufacturer, and any other parties involved in development. Cosmeta's deeper guide to cosmetic formula ownership explains why those rights should be established contractually rather than assumed.
Before fundraising, that distinction can become much more important.
Investors aren't only evaluating what the company sells today. They are trying to understand what the company owns, what it depends on, what can scale, and what they would ultimately be investing in.
If the brand's most valuable product is controlled by an outside manufacturer, the fundraising story is different from a company that owns and controls its quantitative formula.
Neither structure automatically makes a company investable or uninvestable.
But a founder should know which one they have before an investor starts asking.
What Does It Mean to Own a Cosmetic Formula?
Formula ownership means having the contractual rights to the finished formulation according to the applicable development agreement.
For Cosmeta's purposes, 100% formula ownership means the brand receives and controls the finished quantitative formula, including the percentages of the ingredients used in that formulation.
That is much more information than appears on an INCI list.
An ingredient declaration may tell an investor or competitor that the product contains:
Niacinamide.
Ceramide NP.
Squalane.
Peptides.
Panthenol.
But it generally does not reveal the quantitative architecture behind those ingredients.
Formula ownership can provide the brand with visibility into:
Which ingredients are being used
Their percentages
The particular commercial raw materials specified
Which supplier technologies are important to the product
Which ingredients materially influence COGS
How the finished formula can potentially be modified over time
It can also give the brand a foundation for manufacturing the product with another qualified partner if circumstances change.
That is where ownership starts becoming a business issue rather than simply a formulation preference.
Paying for Formulation Does Not Automatically Mean You Own It
This is one of the most important points for a beauty founder to understand before signing a development contract.
Payment and ownership are not necessarily the same thing.
A company can pay development fees and still receive only certain rights to use the finished product.
Another agreement may transfer full ownership.
A private-label supplier may retain control of the underlying formula entirely.
The only reliable answer is in the applicable contracts.
Cosmeta's existing formula-ownership guidance emphasizes the same distinction: legal ownership depends on the development agreement, manufacturing agreement, intellectual-property provisions, and other contractual rights governing the project.
This is why founders should not rely on conversations such as:
“They developed it for us.”
“We paid for it.”
“We've been manufacturing it there for five years.”
“It's our brand, so obviously it's our formula.”
Those facts may be commercially important.
They do not substitute for contractual ownership.
Formula Ownership and Formula Access Are Different
There is another distinction that becomes important during fundraising.
A founder may receive a copy of a formula.
That does not necessarily prove ownership.
Likewise, a company may legally own a formula but have poor documentation surrounding it.
The strongest position is generally much clearer:
The ownership rights are documented, the current quantitative formula is available, and the company understands what it controls.
This is especially important when formulas have been revised over time.
If the company has Formula V3 in one folder, the manufacturer is producing V7, and nobody can clearly document what happened between them, theoretical ownership becomes less useful operationally.
Ownership is strongest when it is paired with control.
Why Investors May Care About Formula Ownership
An investor is not necessarily going to value a beauty company by placing a dollar figure on each Excel formula.
The investment case is much broader.
Current beauty investors and acquirers continue to place substantial weight on growth quality, margins, differentiation, retention, profitability, scalability, and operational discipline. Beauty M&A analysis has also shown buyers placing greater emphasis on bottom-line fundamentals rather than growth at any cost.
Formula ownership becomes relevant because it can affect several of those areas.
It may influence:
Defensibility. Does the company control something competitors cannot simply obtain from the same manufacturer?
Manufacturing flexibility. Could production move if necessary?
Margins. Does the brand know enough about the quantitative formula to identify cost drivers?
Product evolution. Can the company modify the formula as ingredient technology, regulations, or consumer expectations change?
Supply risk. Does the company know which raw materials or suppliers are critical?
Acquisition readiness. Can another company inherit and continue producing the product?
Formula ownership is therefore rarely the whole investment thesis.
It can be an important piece of the infrastructure supporting it.
Your Formula May Be an Intellectual Property Asset, but Use That Phrase Carefully
Cosmetic formulas are frequently described as intellectual property.
That can be appropriate, but the type of intellectual-property protection matters.
A formula is not automatically patented.
It is not protected by trademark simply because it carries a brand name.
And merely calling something “proprietary” does not establish legal rights.
One potentially relevant form of protection is trade secret protection.
The World Intellectual Property Organization specifically identifies formulas and recipes as examples of information that may qualify for trade-secret protection. In general, trade-secret protection depends on the information being secret, commercially valuable because it is secret, and subject to reasonable measures to maintain that secrecy.
That means a quantitative cosmetic formula can potentially form part of a company's confidential know-how or trade-secret portfolio.
But ownership of a formula and qualification for trade-secret protection are related questions, not identical ones.
The specific legal position should be reviewed by qualified counsel.
Owning a Formula Does Not Mean You Own Every Technology Inside It
This distinction matters enormously, particularly as cosmetic formulations increasingly use patented, trademarked, and proprietary supplier technologies.
Imagine a brand owns a moisturizer formula containing a supplier's proprietary ceramide complex.
The brand may own its finished quantitative formula.
It does not thereby acquire ownership of:
The supplier's patent
The supplier's trademark
The supplier's proprietary manufacturing method
The composition of a proprietary raw material beyond the rights disclosed to customers
The supplier's underlying technology
The same applies to patented peptides, encapsulation technologies, biotech ingredients, polymers, delivery systems, fragrances, and other third-party materials.
Formula ownership gives the brand control over its product architecture.
It does not erase third-party intellectual-property rights.
That nuance makes the ownership position more credible, not weaker.
Trade Secret Protection Requires More Than Writing “Confidential” on the Formula
If a company intends to treat its formula or related manufacturing know-how as a trade secret, simply possessing the document isn't enough.
WIPO explains that trade-secret protection generally depends on reasonable steps being taken to maintain confidentiality. Confidentiality agreements and contractual clauses with business partners are examples of measures that may support that protection.
For a beauty company, that raises practical questions:
Who has access to the formula?
Does the contract manufacturer have confidentiality obligations?
Does the formulator?
Do employees need access to the complete quantitative formula?
Where is it stored?
Are obsolete versions clearly separated from the commercial version?
Who can send it to a new supplier?
The point is not to turn a skincare company into an intelligence agency.
It is to treat commercially important information like commercially important information.
Fundraising Creates a Moment When Ownership Gets Examined
Before fundraising, founders control most of the questions being asked about the business.
During due diligence, that changes.
Investors and their advisers may investigate ownership and contractual rights associated with intellectual property and other material business assets. IP due diligence commonly looks at the scope and validity of rights the company owns, claims to own, or licenses from others.
For a beauty company, the exact diligence request will depend on the transaction.
But a founder should not be surprised if questions eventually reach:
Who developed the formulas?
Who owns them?
Where are the agreements?
Are there royalties?
Does the manufacturer have exclusivity?
Can the company transfer production?
Does a former consultant have rights?
Are any formulas licensed?
Does the manufacturer control critical know-how?
Does another party need to consent before manufacturing moves?
These questions are far easier to answer when the contracts were structured properly at the beginning.
Ambiguous Formula Ownership Creates a Different Kind of Fundraising Problem
Suppose an investor discovers that ownership is unclear.
That does not necessarily end the deal.
It does create something that investors generally dislike:
uncertainty.
Now lawyers may need to review old agreements.
The founder may need to contact a former formulator.
A manufacturer may need to sign an assignment.
Someone may disagree about what was originally promised.
The company may discover that it owns some formulas but not others.
The hero product might use a manufacturer base that cannot be transferred.
Every one of those issues consumes time during a process in which the founder would rather be discussing growth.
This is why formula ownership should be cleaned up before fundraising begins, not while a term sheet is moving toward closing.
The Hero Product Deserves the Most Attention
If one SKU drives a large portion of the company's revenue, that formula deserves disproportionate attention before fundraising.
Imagine the business has ten products.
Nine formulas are perfectly documented and owned.
The tenth generates 70% of sales and is owned by a contract manufacturer.
From a diligence standpoint, the percentages matter far more than the product count.
For a hero product, I would want the company to understand:
Who owns the formula
Who owns associated intellectual property
Whether the quantitative formula is available
Whether the commercial version is correctly documented
Whether critical raw materials are identifiable
Whether stability and testing records exist
Whether the package has been validated
Whether another qualified manufacturer could theoretically produce it
Whether any contractual restrictions affect transfer
The product carrying the company's valuation should not be the least understood asset in the portfolio.
Formula Ownership Is Not the Same as Manufacturing Portability
This may be one of the most important distinctions for founders preparing to raise money.
Imagine a company owns the quantitative formula.
Excellent.
Can another manufacturer actually produce it?
A percentage list alone does not necessarily capture everything needed for an efficient manufacturing transfer.
Commercial portability can also depend on documentation around:
Raw-material specifications
Supplier grades
Finished-product specifications
Manufacturing instructions
Packaging
Stability
Quality standards
Scale-up history
Cosmeta's article on Custom Formulation vs. Contract Manufacturing explains why formulation development and production are related but distinct functions.
This creates a useful distinction:
Formula ownership gives you the right to control the formula.
Technology transfer gives you the information needed to move it successfully.
A fundraising-ready brand should ideally understand both.
Why Manufacturer Independence Can Matter to an Investor
A brand does not need to manufacture its own cosmetics to be independent.
Contract manufacturing is normal throughout the beauty industry.
The strategic question is whether the company is choosing to stay with its manufacturer or unable to leave.
Those situations can look identical while everything is going well.
They look very different when:
Pricing changes
Minimums increase
Capacity becomes limited
Quality issues occur
Lead times become unacceptable
The manufacturer is acquired
The brand outgrows the facility
Another manufacturer better supports international expansion
If the brand owns its formula and maintains the information needed for transfer, it has options.
That doesn't mean it should exercise them.
Options themselves have value.
Formula Ownership Can Strengthen Negotiating Leverage
A founder who can realistically move production is in a different negotiating position from one who cannot.
That may affect conversations around:
Unit pricing
Minimum order quantities
Production slots
Payment terms
Raw-material substitutions
Ingredient sourcing
Packaging
Lead times
A strong manufacturer relationship should be collaborative.
Formula ownership is not about using portability as a threat.
It simply prevents all of the company's technical leverage from sitting on the other side of the table.
That can become increasingly important as the brand grows.
Owning the Quantitative Formula Can Improve COGS Visibility
Fundraising often puts more attention on product economics.
If the brand knows the quantitative formula, it can more intelligently evaluate what is driving cost.
Perhaps the hero peptide adds $0.18 per unit.
Perhaps the ceramide system adds $0.60.
Perhaps five supporting extracts collectively add $0.90 while contributing almost nothing to the product's differentiation.
Perhaps the formula is efficient and the real cost problem is packaging.
Without quantitative information, the brand may know the cost of finished bulk but have limited visibility into the architecture behind it.
That makes intelligent cost optimization harder.
Cosmeta's guides to COGS in Cosmetic Manufacturing and How to Price a Skincare Product explore why formulation decisions and product economics need to be considered together.
Investors Do Not Want You to Destroy the Product to Improve Margin
Ownership also gives the company a better basis for selective cost optimization.
Suppose an investor believes there is room to improve gross margin.
The goal should not be:
Remove everything expensive.
A product may depend on a particular emollient for its signature skin feel.
A specialty polymer may create the elegant break during application.
A proprietary active may be central to the claims story.
Those are not necessarily where the savings should come from.
A quantitative formula allows the team to distinguish:
cost that creates consumer value
from
cost that merely accumulated during development.
That distinction can protect the product during aggressive growth.
Ingredient Percentages Can Matter to the Value of the Product Story
Beauty brands increasingly communicate quantitative ingredient claims.
5% niacinamide.
10% vitamin C.
A defined level of an active complex.
If a brand makes ingredient percentage part of its positioning, it should know exactly what it controls.
The front of a package may say:
Ceramide Complex
But what does the formula actually contain?
Which complex?
At what percentage?
How much active ceramide is present inside the supplied raw material?
The same applies to peptides, vitamin C technologies, retinoids, botanical standardizations, and other hero ingredients.
Owning the quantitative formula gives the company visibility into the substance behind the marketing story.
For an investor evaluating a science-led brand, that can be meaningful.
“Proprietary Formula” Should Mean Something
The word proprietary appears frequently in beauty.
Sometimes it means the brand owns a genuinely unique formula.
Sometimes it means a manufacturer made a small modification to a stock base.
Sometimes it means nothing more than the brand considers its combination of ingredients distinctive.
Before fundraising, I would want the company to be precise internally even if consumer-facing language remains simple.
What exactly is proprietary?
The quantitative formula?
A patented technology?
A trademarked complex?
A supplier exclusive?
A trade secret?
A manufacturing process?
A unique fragrance?
The clearer the company is about its actual assets, the stronger the diligence conversation becomes.
Formula Ownership Does Not Automatically Make the Product Defensible
This is another place where the conversation needs nuance.
A brand could own a perfectly ordinary moisturizer formula containing widely available ingredients.
Ownership gives the company control.
It does not magically make the product difficult to compete with.
Likewise, a private-label product can become enormously successful through:
Brand equity
Community
Distribution
Consumer loyalty
Packaging
Retail relationships
Marketing execution
Formula ownership is therefore best understood as one layer of defensibility and control.
Its strategic value becomes greater when the formula itself contributes meaningfully to why the product succeeds.
Custom Formulation Creates the Strongest Ownership Case When the Formula Is Part of the Moat
Custom development becomes particularly relevant when a brand wants the product itself to contribute to differentiation.
That could include control over:
Active percentages
Ingredient forms
Multi-active architecture
Sensory performance
Ingredient exclusions
Retailer requirements
Certification strategy
Delivery technology
Packaging compatibility
Claims
Product format
With custom formulation, the brand can structure the development agreement around ownership from the beginning.
Cosmeta's current custom-development model provides full ownership of formulations developed exclusively for the client's project, allowing the brand to manufacture with the partner of its choice after development.
That makes ownership deliberate rather than something the founder hopes to negotiate years later.
Private Label Can Still Be the Right Choice Before Fundraising
Formula ownership should not become another rule that tells every founder they chose the wrong development model.
Private label can make excellent sense.
It can offer:
Faster commercialization
Lower initial development investment
Proven manufacturing systems
Lower technical burden
Easier market testing
A founder might deliberately launch a private-label product, validate demand, build distribution, and later decide whether a proprietary formula is justified.
That can be a highly rational capital strategy.
The important thing is knowing the trade-off.
If the manufacturer owns the underlying formula, the founder should not build the fundraising narrative around owning proprietary formulation IP that the company does not actually possess.
Do You Need to Reformulate Before Raising Money?
Not necessarily.
If a manufacturer owns your formula, the answer is not automatically:
Throw everything away and start over.
First determine what rights you actually have.
The existing manufacturer relationship may be excellent and contractually secure.
The brand may have strong economics and little technical need to move.
The product may not rely on formula uniqueness as part of the investment thesis.
In other situations, converting an important SKU to a proprietary custom formula before fundraising may make strategic sense.
That decision should be based on:
Importance of the product
Existing ownership rights
Revenue concentration
Differentiation
Manufacturer relationship
Cost of redevelopment
Timing
Investor strategy
Long-term business goals
Ownership is a strategic choice.
It should not become a reflex.
What Should a Founder Review Before Fundraising?
Before investor diligence begins, a founder should have a clear internal answer to several questions.
Who owns each formula?
Do not assume. Verify the contracts.
Do we possess the current quantitative formulas we are entitled to possess?
Make sure the commercial versions are identifiable.
Are there any royalties, licenses, exclusivities, or restrictions?
Understand continuing obligations.
Who owns modifications made during manufacturing?
This is particularly important if the original laboratory formula has changed.
Can the formula be transferred?
Ownership and portability are different.
What third-party technology is incorporated?
Identify supplier-controlled ingredients, trademarks, patented technologies, and exclusives.
How is confidential information protected?
Trade-secret value depends in part on maintaining secrecy and taking reasonable protective measures.
Are the hero products better documented than the rest?
They should be.
This is the kind of housekeeping that feels unimportant until suddenly it isn't.
Clean Up Ownership Before the Investor Creates the Deadline
One of the worst times to renegotiate formula ownership is when the other party knows you need the agreement signed to close a financing round.
The leverage is different.
A contract manufacturer or former developer may be completely cooperative.
They may also have no obligation to transfer rights they never agreed to transfer.
Resolving the question early gives the founder time to:
Review agreements
Obtain legal advice
Clarify ownership
Secure assignments where appropriate
Organize documentation
Redevelop a formula if necessary
Evaluate alternate manufacturing
It also keeps the fundraising story cleaner.
Instead of saying:
“We think we own it, but our attorney is checking.”
the founder can give a documented answer.
That difference may sound small.
In due diligence, clarity has value.
Do Not Wait Until an Exit Either
Fundraising is not the only reason to establish ownership.
The same questions can emerge during:
Acquisition
Licensing
Joint ventures
International expansion
Manufacturer changes
Distributor relationships
Strategic partnerships
WIPO notes that trade-secret information can be sold, licensed, shared with business partners, and used strategically as part of a company's broader intellectual-property portfolio.
A founder who establishes control early creates more possible future transactions.
That is the broader business value.
Key Takeaways
Formula ownership should be determined from contracts, not assumptions. Paying for development does not by itself establish what rights a beauty brand owns.
For brands preparing to raise capital, ownership of the finished quantitative formula can provide greater visibility into ingredient percentages, product architecture, COGS, supplier dependencies, manufacturing flexibility, and future reformulation.
A cosmetic formula may potentially form part of a company's trade-secret portfolio when it meets the applicable requirements, including secrecy, commercial value derived from secrecy, and reasonable measures to protect it.
Ownership does not give a brand rights to third-party patented ingredients, trademarks, supplier technologies, or other intellectual property incorporated into the product.
And formula ownership is not mandatory for every successful or investable beauty brand. Private label and manufacturer-controlled formulations can support excellent businesses.
The essential point is simpler:
Know exactly what the company owns before asking someone else to invest in it.
Cosmeta's Perspective
I think founders often view formula ownership as something they can clean up later.
Later tends to arrive at the least convenient moment.
A hero product takes off.
A retailer wants more volume.
The manufacturer raises minimums.
An investor starts diligence.
An acquisition conversation begins.
Suddenly the formula that once looked like a technical document is attached to real revenue and real company value.
That is when ownership matters.
For me, the bigger advantage isn't simply being able to tell an investor, “We own our formula.”
It is what ownership allows the company to do.
Know the percentages.
Understand the cost structure.
Keep the product current as ingredient technology changes.
Move production if the business outgrows a manufacturer.
Protect the formulation strategy that differentiates the product.
And decide how the product evolves instead of having those decisions made by whoever happens to control the formula.
Formula ownership doesn't create a successful brand.
Consumer demand still has to do that.
But once you've created something consumers genuinely want, controlling the product underneath that demand can become a very valuable place to be.
Ready for the Next Step
Before fundraising, put formula ownership on the same diligence list as trademarks, financials, contracts, and cap-table documentation. Know which formulas the company owns, which it licenses or buys through a manufacturer, what quantitative information is available, and whether the hero products can move with the company as it grows.
FAQs
-
No. Paying development fees does not by itself determine ownership. Formula ownership depends on the applicable contracts, including the formulation agreement, manufacturing agreement, intellectual-property provisions, and any later assignments or technology-transfer agreements. Cosmeta's formula-ownership guide explains why these rights should be established explicitly.
-
No. A beauty company can raise capital or be acquired without owning every formula. Private-label and manufacturer-controlled products can support very successful businesses. Formula ownership becomes more strategically important when proprietary formulation, manufacturing flexibility, ingredient control, or product-level differentiation forms an important part of the investment thesis.
-
It can be. WIPO identifies formulas as information that may qualify for trade-secret protection. In general, the information must be secret, have commercial value because it is secret, and be subject to reasonable measures intended to preserve that secrecy. Whether a specific cosmetic formula qualifies depends on the applicable facts and law.
-
At minimum, a founder should understand who owns each important formula, whether the current quantitative version is documented, whether any licenses or restrictions apply, which third-party technologies are incorporated, and whether the product can realistically be manufactured elsewhere if necessary. Depending on the company and transaction, investors may also review stability, specifications, claims substantiation, supplier relationships, and manufacturing agreements.
-
Not automatically. The decision depends on how important formula ownership and product differentiation are to the business. If the current private-label product has strong margins, secure manufacturing, loyal consumers, and little strategic need for proprietary formulation, redeveloping it solely for fundraising may add unnecessary cost and risk. If a manufacturer-controlled hero formula represents a major portion of company value and long-term control is important, custom redevelopment may deserve consideration before fundraising.
